Clinical Trials Browser

Phase 1 × Recurrence × Bortezomib × Clear all

NCT01497093 2020-04-07

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1 Completed

34 enrolled

Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01359657 2016-03-16

Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Phase 1 Completed

46 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT00383474 2015-04-15

Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase

Phase 1 Completed

35 enrolled

LymphoidOther hematologic neoplasm

Blast Crisis, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Recurrence, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00994500 2013-07-02

Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma

Phase 1 Completed

20 enrolled

CNSLymphoidSarcoma

Familial ependymoma, Astrocytoma, Burkitt Lymphoma, Medulloblastoma, Meningioma, Oligodendroglioma, Recurrence, Lymphoma, Large B-Cell, Diffuse, Choroid Plexus Neoplasms, Lymphoma, Large-Cell, Anaplastic, Optic Nerve Glioma, Lymphoma, Extranodal NK-T-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT00382954 2010-09-29

Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML

Phase 1 Completed

55 enrolled

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT00080405 2009-03-27

Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma

Phase 1 Completed

40 enrolled

Plasma cell

Multiple Myeloma, Recurrence